Abstract
Objective Epilepsy is a chronic neurological disorder related to various etiologies and the prevalence of active epilepsy is estimated to be between 4-10 per 1000 individuals having a significant role of genetic mutations. Next-Generation Sequencing (NGS) panels are utilized for genetic testing, still, a substantial proportion of the results remain uncertain and are not considered directly causative of epilepsy. This study aimed to reevaluate pediatric patients diagnosed with epilepsy who underwent genetic investigation using NGS panels, focusing on inconclusive variant findings or multiple Variants of Uncertain Significance (VUSs).
Methods A subgroup of pediatric patients aged 0-25 years, diagnosed with epilepsy, who underwent genetic investigation with an NGS epilepsy panel at the Child Neurology Unit, The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, between 2018-2022 through Invitae, was reevaluated. Patients with inconclusive variant findings or multiple VUSs in their test results were included. Genetic data were analyzed, focusing on identifying potentially pathogenic variants and frequent genetic combinations.
Results Two unrelated potentially pathogenic variants were identified in the SCN9A and QARS1 genes. A frequent genetic combination, RANBP2&RYR3, was also observed among other combinations. The RANBP2 gene consistently co-occurred with RYR3 variants in uncertain results, suggesting potential pathogenicity. Analysis of unaffected parents’ data revealed certain combinations inherited from different parents, suggesting specific gene combinations as potential risk factors for the disease.
Significance This study highlights the importance of reevaluating genetic data from pediatric epilepsy patients with inconclusive variant findings or multiple VUSs. Identification of potentially pathogenic variants and frequent genetic combinations, such as RANBP2&RYR3, could aid in understanding the genetic basis of epilepsy and identifying potential hotspots.
Plain Language Summary We have performed a retrospective analysis on a subpopulation of pediatric patients diagnosed with epilepsy, we have found that specific genetic variants were repeatable indicating their potential pathogenicity to the disease.
Key points
60% of pediatric patients undergoing genetic testing receive an uncertain result emphasizing the complexity of genetic interpretation in epilepsy diagnostics.
Pathogenic variants in genes like SCN1A were common, underlining the importance of targeted gene sequencing.
Variants in genes like SCN9A and QARS1, currently classified as VUSs, showed consistent presence in epilepsy patients, indicating potential pathogenicity.
Specific genetic combinations, such as RANBP2&RYR3, were frequently observed among uncertain results, suggesting potential pathogenicity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Zuckerman STEM Leadership Program and Israel science foundation (ISF) grants 1994/21 and 352/21.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of The Sheba Fund for Health Services and Research gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
title change and minor changes in the manuscript format
Data Availability
All data produced in the present study are available upon reasonable request to the authors